MedTrace Logo

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

NCT05212922 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-03-20

No results posted yet for this study

Summary

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

Conditions

  • HCC
  • NSCLC Stage IIIB
  • NSCLC Stage IV

Interventions

DRUG

YH001 + Toripalimab

YH001 + Toripalimab

Sponsors & Collaborators

  • Eucure (Beijing) Biopharma Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Rong Chen, Ph.D · Eucure (Beijing) Biopharma Co., Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-12-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • Armenia
  • Australia
  • Austria
  • China
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212922 on ClinicalTrials.gov